Nps Pharmaceuticals Incorporated (NASDAQ: NPSP)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a report released on Wednesday. They currently have a $22.00 target price on the stock, up from their previous target price of $19.00.
The analysts wrote, “NPSP announced the buy-back of ex-US rights from Takeda for Gattex (Revestive in Europe) and Natpara (Preotact in Europe) for 6M newly issued NPSP shares and $30M in cash or shares if combined global sales reach $750M. Recall that Takeda acquired the ex-US rights for these products through its acquisition of Nycomed in 2011. … We view this as a positive transaction for NPSP as Takeda had not put effort into commercialization.”
Shares of Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) traded down 0.91% during mid-day trading on Wednesday, hitting $9.79. Nps Pharmaceuticals Incorporated has a 52 week low of $6.32 and a 52 week high of $11.22. The stock’s 50-day moving average is currently $8.36. The company’s market cap is $850.8 million.
Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) last posted its quarterly earnings results on Thursday, February 21st. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.05. The company had revenue of $27.10 million for the quarter, compared to the consensus estimate of $28.93 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Analysts expect that Nps Pharmaceuticals Incorporated will post $-0.18 EPS for the current fiscal year.
A number of other firms have also recently commented on NPSP. Analysts at Jefferies Group raised their price target on shares of Nps Pharmaceuticals Incorporated from $15.00 to $16.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Nps Pharmaceuticals Incorporated from $16.00 to $20.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Brean Murray downgraded shares of Nps Pharmaceuticals Incorporated from a “buy” rating to a “hold” rating in a research note to investors on Tuesday.
Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $16.33.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
